Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing Event
Lucid Diagnostics (Nasdaq: LUCD) successfully completed its first major directly-contracted #CheckYourFoodTube Precancer Testing Event in partnership with the Fort Worth Fire Department (FWFD) and Front Line Mobile Health. Nearly 200 firefighters underwent testing using Lucid's EsoGuard® Esophageal DNA test and EsoCheck® Esophageal Cell Collection Device.
FWFD Fire Chief Jim Davis emphasized the importance of early detection, citing his personal loss to esophageal cancer. Lucid's President and COO, Shaun O'Neil, highlighted the potential for directly contracting with self-insured entities to contribute to long-term revenue growth. The event garnered local media coverage and addressed the increased risk of esophageal cancer among firefighters.
Lucid Diagnostics (Nasdaq: LUCD) ha completato con successo il suo primo importante evento di Test Pre-cancerogeni #CheckYourFoodTube in collaborazione con il Dipartimento dei Vigili del Fuoco di Fort Worth (FWFD) e Front Line Mobile Health. Quasi 200 vigili del fuoco hanno partecipato ai test utilizzando il test del DNA EsoGuard® e il Dispositivo di Raccolta Cellulare EsoCheck® di Lucid.
Il Capo dei Vigili del Fuoco di FWFD, Jim Davis, ha sottolineato l'importanza della diagnosi precoce, citando la sua perdita personale a causa del cancro esofageo. Il Presidente e COO di Lucid, Shaun O'Neil, ha evidenziato il potenziale per contratti diretti con entità auto-assicurate per contribuire alla crescita dei ricavi a lungo termine. L'evento ha attirato l'attenzione dei media locali e ha affrontato il rischio aumentato di cancro esofageo tra i vigili del fuoco.
Lucid Diagnostics (Nasdaq: LUCD) completó con éxito su primer evento importante de pruebas de cáncer precoces directamente contratadas #CheckYourFoodTube en colaboración con el Departamento de Bomberos de Fort Worth (FWFD) y Front Line Mobile Health. Casi 200 bomberos se sometieron a pruebas utilizando el test de ADN EsoGuard® y el Dispositivo de Recogida de Células EsoCheck® de Lucid.
El Jefe de Bomberos de FWFD, Jim Davis, enfatizó la importancia de la detección temprana, citando su pérdida personal a causa del cáncer esofágico. El Presidente y COO de Lucid, Shaun O'Neil, destacó el potencial de contratar directamente con entidades autoaseguradas para contribuir al crecimiento de los ingresos a largo plazo. El evento recibió cobertura de los medios locales y abordó el mayor riesgo de cáncer esofágico entre los bomberos.
Lucid Diagnostics (나스닥: LUCD)는 포트 워스 소방서 (FWFD) 및 프론트 라인 모바일 헬스와 협력하여 첫 번째 주요 직접 계약 #CheckYourFoodTube 조기 암 검사 이벤트를 성공적으로 완료했습니다. 거의 200명의 소방관이 Lucid의 EsoGuard® 식도 DNA 검사와 EsoCheck® 식도 세포 채취 장치를 사용하여 검사를 받았습니다.
FWFD 소방서장 Jim Davis는 개인적으로 식도암으로 인한 손실을 언급하며 조기 발견의 중요성을 강조했습니다. Lucid의 사장 겸 COO인 Shaun O'Neil은 자가 보험을 사용하는 기관과 직접 계약하여 장기 수익 성장에 기여할 가능성을 강조했습니다. 이 이벤트는 지역 언론의 관심을 받았고 소방관들 사이의 식도암 위험 증가 문제를 다루었습니다.
Lucid Diagnostics (Nasdaq: LUCD) a réalisé avec succès son premier grand événement de test de pré-cancer #CheckYourFoodTube sous contrat direct en partenariat avec le Service d'incendie de Fort Worth (FWFD) et Front Line Mobile Health. Près de 200 pompiers ont subi des tests utilisant le test ADN EsoGuard® et le Dispositif de collecte de cellules EsoCheck® de Lucid.
Le chef des pompiers de FWFD, Jim Davis, a souligné l'importance du dépistage précoce, citant sa perte personnelle due au cancer de l'œsophage. Le président et COO de Lucid, Shaun O'Neil, a souligné le potentiel de contrats directs avec des entités auto-assurées pour contribuer à la croissance des revenus à long terme. L'événement a remporté une couverture médiatique locale et a abordé le risque accru de cancer de l'œsophage parmi les pompiers.
Lucid Diagnostics (Nasdaq: LUCD) hat erfolgreich sein erstes großes direkt vertraglich geregeltes #CheckYourFoodTube Krebsfrüherkennungs-Event in Partnerschaft mit der Feuerwehr Fort Worth (FWFD) und Front Line Mobile Health abgeschlossen. Fast 200 Feuerwehrleute haben sich Tests unterzogen, bei denen der EsoGuard® Esophageal DNA-Test und das EsoCheck® Esophageal Cell Collection Device von Lucid verwendet wurden.
FWFD Feuerwehrchef Jim Davis betonte die Bedeutung der Früherkennung und verwies auf seinen persönlichen Verlust durch Speiseröhrenkrebs. Lucids Präsident und COO, Shaun O'Neil, hob das Potenzial direkt vertraglicher Vereinbarungen mit selbstversicherten Organisationen hervor, um zum langfristigen Umsatzwachstum beizutragen. Die Veranstaltung erhielt lokale Medienberichterstattung und behandelte das erhöhte Risiko von Speiseröhrenkrebs unter Feuerwehrleuten.
- Nearly 200 firefighters underwent EsoGuard® Esophageal DNA testing
- First major directly-contracted #CheckYourFoodTube event for Lucid Diagnostics
- Potential for long-term revenue growth through direct contracting with self-insured entities
- Local media coverage of the event, increasing visibility for Lucid's products
- None.
Event held at
Front Line contracted with Lucid to hold this event, where nearly 200 firefighters, deemed to be at risk for esophageal precancer, underwent testing using Lucid's EsoGuard® Esophageal DNA test at the FWFD training facility. Front Line staff worked closely with Lucid clinical personnel and
"Hosting this esophageal precancer testing event is an important step in our commitment to the health and safety of our firefighters," said FWFD Fire Chief Jim Davis. "Having experienced the loss of my own father to esophageal cancer, the critical nature of early detection of esophageal precancer hits extremely close to home for me. I am a huge proponent of EsoGuard and its ability to help ensure that our team members can continue to effectively serve our community."
"We commend Chief Davis and Dr. Smith for demonstrating their commitment to the health and safety of first responders who risk their lives to serve their community, and for partnering with us on a highly successful event," said Shaun O'Neil, Lucid's President and Chief Operating Officer. "We look forward to collaborating with Front Line on additional events with other clients. We believe that directly contracting with self-insured entities, including employers, unions, and municipal departments, as well as medical care providers who service them, will meaningfully contribute to long-term revenue growth."
Local
Firefighters have a
To learn more about hosting a #CheckYourFoodTube Precancer Testing Event, please visit www.esoguard.com/request-an-event.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
Forward-Looking Statements
This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid's clinical and preclinical studies; whether and when Lucid's products are cleared by regulatory authorities; market acceptance of Lucid's products once cleared and commercialized; Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, Lucid continues to monitor the COVID-19 pandemic and the pandemic's impact on Lucid's businesses. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid's future operations, see Part I, Item 1A, "Risk Factors," in Lucid's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-holds-first-major-directly-contracted-esoguard-checkyourfoodtube-precancer-testing-event-302217686.html
SOURCE Lucid Diagnostics
FAQ
What was the purpose of Lucid Diagnostics' #CheckYourFoodTube Precancer Testing Event?
How many firefighters were tested at the Lucid Diagnostics event in Fort Worth?
What is the increased risk of esophageal cancer for firefighters according to the PR?
Who were the partners involved in Lucid Diagnostics' (LUCD) testing event?
